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Abstract	
Introduction. Atopy and ear, nose and throat (ENT) diseases are frequently associated; however, no 
clinical tool has been proposed so far to discriminate which patients could be atopic and therefore 
deserving of a further immunoallergological evaluation.  Objective. The aim of this study was to assess 
and validate a set of dichotomous responses suitable for predicting the presence of atopy in adults’ 
patients. Methods. An 11-item questionnaire called "atopy index inventory (AII), composed by four 
questions regarding the clinical history for allergic disease and seven questions evaluating the presence 
of the most frequent clinical signs affecting allergic patients, was developed and administered to 226 
adult subjects (124 atopic subjects and 102 healthy, not atopic subjects). The atopic condition was 
proved by an immunoallergological evaluation according to the diagnostic criteria of the EAACI 
guidelines. Internal consistency and clinical validity were tested. Results. In healthy subjects, the first 
4 variables of the AII returned a 100% correct response (all answered “no”) and were defined as 
“decisive” responses. In the logistic regression analysis, when decisive items were negative, the atopic 
condition was confirmed when answering “yes” to at least 3 “probability” items (cut-off = 2.69). The 
difference of AII scores between allergic and healthy group was significant using the Mann-Whitney U 
test (p < 0.0001). Sensitivity and specificity of the AII were 0.97 and 0.91, respectively, with a true 
predictive value of 0.92 and a false predictive value of 0.97. The ROC curve showed an area of 0.94, 
with an odds ratio of 0.88 [interval of confidence (95%): 0.87–0.97, p=0.0001]. Internal consistency by 
the Cronbach alpha coefficient was 0.88. Conclusion. The AII has proved to be a brief, simple and 
sufficiently accurate tool for screening ENT patients in search of atopic individuals and allow their 
clinical management. 
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INTRODUCTION 
Atopy is a polygenic disorder characterized by the expression of certain allergic hypersensitivity 
reactions, mediated by IgE, to the exposure to allergens. As a consequence, atopy produces allergy with 
the typical symptoms of asthma, rhino conjunctivitis, or eczema. Atopy has been associated with several 
ear, nose and throat (ENT) disorders, such as otitis media with effusion [1-4], adenoid hypertrophy [5-
7], rhinitis and sinusitis [8-9], Ménière's disease [10-12] and Reinke's edema [13]. When a patient 
is referred for one of these common diseases, the ENT specialists usually address the existence 
of an allergic substrate by means of a direct, time-consuming interview or empiric treatments [14]. 
If an allergic condition is only marginally suspected, the patient is then frequently referred for 
immunoallergological evaluation.  
Various clinical measures of allergy (e.g., skin-prick test positivity, elevated total IgE, and specific IgE 
titer) and questionnaires have been assessed in a number of studies, but none of these tools have 
been studied to screen for an atopic condition [15, 16]. In particular, the questionnaires on atopy [17-
22] are aimed at monitoring clinical symptoms, determining the clinical evolution of allergic 
sensitization, or quantifying the effects of therapy or changes in the quality of life but none of the 
questionnaires are targeted for screening purposes. Furthermore, it is widely acknowledged that the 
diagnosis of atopy is not very straightforward [23, 24] due to its polygenic nature and because an 
increase of total and specific IgE is not a necessary landmark for identifying atopic individuals [23]. 
In fact, the correlation between skin tests and in vitro tests for specific IgE is not always very 
strong since mucosal and skin IgE may be different from blood IgE [24 - 27]. Moreover, currently 
available allergenic extracts manufactured by different companies for allergy testing are very 
heterogeneous [28, 29], and some allergens, such as storage mites (glycyphagidae and acaridae), 
although considered important, are not always included in the testing batteries [30].  
The aim of this study was to assess and validate a questionnaire to identify patients requiring further 
allergological evaluation. For this purpose, we developed and assessed AII that could be easily and 
rapidly administered that could expedite the assessment of potentially atopic patients in an ENT 
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clinical setting and define which patients should be referred for further investigation of a possible 
allergic condition since it may have practical implications for treatment. 
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MATERIALS AND METHODS 
Validation of the AII 
Item generations were founded: a) on the international literature review through Medline database; 
b) on the most commonly reported symptoms related to atopy [15-22] and c) on the most commonly 
routine questions posed in clinical practice. The resulting screening questionnaire denominated 
the Atopy Index Inventory (AII) included 11 items aimed at identifying the allergic condition. (Table 
1)  
The statistical analysis of this study consisted of two separate phases: scale development and then 
reliability and validity analysis.  
According to the STARD guidelines, we tested the AII on 226 consecutive subjects attending our 
outpatient clinic between 2012 and 2015, at the time of their first referral visit for audiological 
evaluation. Patients were administered the AII as part of the clinical assessment, and no other 
questions concerning  the possibility of “atopy” were asked. The ENT specialists filled out the AII. 
All 226 subjects were then referred for immunoallergological evaluation. All were tested with skin 
tests using a standardized method: 1) prick tests for the most common inhalants, cow milk proteins, 
ovoalbumin, and water extract from wheat flour and 2) prick tests for tomato, potato, apple, and 
carrots (fresh foods). Histamine was used as a positive control and extract diluent as a negative 
control. Patients with negative prick tests were further investigated by an intradermal test with a 
Dermatophagoides mixture. Subsequently, the 226 patients were classified by the immunologists 
into two subgroups according to the immunoallergological results into the  "atopic group” and 
“control group” according to the EAACI guidelines [19].  
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Atopic group 
This group included 124 individuals, 76 females (age range 4–79 years, mean 36.8 ± 19.11) and 48 
males (age range 6–70 years, mean 32.7 ±18.97). According to the EAACI guidelines [19], this group 
included those patients with a positive skin test to at least one of the allergens tested and/or positive 
on an intradermal test (wheal > 5 mm) and/or elevated total IgE > 260 U.I./ml and/or specific IgE > 
0.70 KU/l, allergic rhinopathy according to The International Consensus statement on Allergy and 
Rhinology: Allergic Rhinitis [31] and/or treated with immunotherapy with success.  
 
Control group 
This group comprised 102 individuals: 61 females (age range: 19–74 years, mean 36.0±14.3) and 41 
males (age range 19–74 years, mean 38.8 ±17.6). The “control group” was constituted by all (non-
atopic) patients who tested negative on all the previously reported parameters at the 
immunoallergological evaluation. 
The participation in the study for both groups was voluntary, and subjects were not compensated. 
Patients signed a written informed consent for the publication of the results. The research was 
conducted ethically in accordance with the World Medical Association Declaration of Helsinki of 1975, 
as revised in 2008; all the procedures contributing to this work comply with the ethical standards of 
the relevant national and institutional guidelines on human experimentation and have been approved 
by the Ethics Committee of the Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico of Milan, 
Italy (n.2174- 2016). This study also complies with the Standards for Reporting of Diagnostic 
Accuracy Studies [32]. Informed consent was obtained from all individual participants included in the 
study. Patients’ anonymity has been guaranteed.  
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Statistical analysis 
Data were collected in an Excel datasheet, imported and analyzed by means of the R-program for 
statistical computing (R core team, 2015) using the package MASS to carry out logistic regression, 
and the packages ROCR and AUC to estimate and plot different performance measures, such as 
optimum cut-off, accuracy, sensitivity and specificity, odds, true and false predictive value (TPV and 
FPV, respectively) and interval of confidence (IC). The internal consistency of the 11 tests was 
assessed using the Cronbach alpha coefficient by the package PSY. (CRAN, R core team, 2015) The 
presence of ceiling and floor effects was evaluated on the basis of the percentage of patients with 
the maximum or minimum AII score and was considered present if this was the case in 15% or more 
of the patients [33]. The Kaiser-Meyer Olkin (KMO) measure of sampling adequacy and the Bartlett 
Test of Sphericity (BTS) were conducted on the data prior to factor extraction to ensure that the 
characteristics of the data set were suitable for the exploratory factor analysis (EFA) to be conducted. 
For the EFA, the number of factors to extract was determined by the scree plot and Kaiser’s criterion 
of unity (i.e., Eigen values > 1). Principal component analysis with Varimax rotation was used to 
maximize the amount of variance explained by the instrument items. Spearman’s rank correlation 
was used for evaluating the relationship among the 11 items. The fitted values of the responses 
obtained from the logistic regression were the starting point to estimate the probabilities to 
assign a subject to a group. Since individual items differed in their association with “atopy”, each 
item was weighted by its odds ratio in favor of “atopy”. The fitted values obtained with logistic 
regression were turned into a binary class decision by choosing a cut-off using the package ROCR. 
The presence of a normal distribution was assessed by a Shapiro-Wilks normality test; a goodness-
of-fit test was used to verify the Poisson distribution. A Wilcoxon Mann-Whitney nonparametric 
test was used to test significant differences between the two groups (p< 0.05). 
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RESULTS  
The Cronbach alpha coefficient was 0.8 [interval of confidence (95%): 0.86–0.90], indicating a high 
intrinsic reliability of the AII’s items. The adequacy of the sample was confirmed by KMO sampling 
adequacy analysis, yielding an index of 0.889. The Bartlett measure of sampling adequacy (anti-image 
correlation matrix) for the 11 items of the AII was highly significant (χ2 = 1065.3, df = 55, p < 0.0001), 
indicating that the data satisfied the psychometric criteria for the factor analysis to be performed 
based on data distribution characteristics. Ceiling and floor effects were absent. Exploratory factor 
analysis showed a high interrelationship among all the AII items, showing that all eleven items have to 
be included in the instrument. The AII scores between atopic and control group were significantly 
different (p < 0.0001). 
The first 4 items of the AII gave a 100% correct response (“no”) in healthy subjects (control group), so 
these four items were confirmed as “decisive” responses (“s”). (Table 2) The ROC curve was calculated 
including the entire group of allergic and nonallergic subjects. Results showed an odds ratio of 0.88 
with an area under the curve (AUC) value of 0.94, and suggested that a cutoff score of 2.69 was able 
to accurately identify atopic subjects with a sensitivity value of 0.97 and specificity of 0.91. TPV was 
0.92, and FPV 0.97. [interval of confidence (95%): 0.87–0.97, p=0.0001] (Figure 1) 
Using an Excel datasheet, it was possible to fit a formula in which each of the responses obtained from 
the newly tested subjects (potentially “atopic” or “healthy”) could be singularly multiplied by the 
regression coefficients, including the intercept. In this proposed formula, the discriminating threshold 
value became: Y = ln (p /(1 − p) = −0.348, where Y> 0.348 identifies the TRUE condition (“atopic”).  
The scores have also been recalculated as weighted means, adding the first 4 AII items and weighting 
all 11 AII items with their accuracy, as reported in Table 2. Logistic regression was carried out with 
the 7 “probability” items to obtain the regression coefficients and their significance as shown in Table 
3. Age and sex did not significantly contribute to any reduction of residual deviance.  
9 
 
A threshold could be established by plotting the Poisson distributions of the responses of atopic and 
healthy individuals (Figure 2). The crossing of the two plots was confirmed at a value of 2.69, which 
was selected as the cut-off point, providing a 94% probability of correctly identifying a patient with 
an “atopic” condition.  
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DISCUSSION 
The impact of atopy on several ENT disorders has not been fully clarified so far, and therefore an easy 
and rapid inventory that could expedite the assessment of potentially allergic patients and reduce the 
referral rate to immuno-allergologists is highly desirable.  
The results showed strong internal consistency and clinical and external validity. Summarizing the 
results of the statistical analysis, we can conclude that an “atopic condition” was confirmed if the 
answer was “yes” to at least one of the “decisive” questions (s) or to at least three “probability” 
questions (r), with high sensitivity and specificity (0.97 and 0.91, respectively), a true predictive 
value of 0.92 and a false predictive value of 0.97. The Cronbach alpha coefficient of 0.88 is generally 
considered ‘‘good’’ and greater than 0.9 ‘‘excellent,’’ whereas a value greater than 0.7 is often 
considered satisfactory. In the present study, the first 4 AII items were able to give a satisfactory 
test, while the inclusion of at least one of the other 7 AII items were able to give a good test, even 
if the inclusion of all the 11 variables gave a result near to excellent (alpha = 0.88). 
The strength of this study relies on the unequivocal identification of atopic subjects based on the 
logistic regression analysis [19].  Furthermore, as far as we know, no other comparable 
questionnaires are available to act as a “gold standard” to validate the AII. The inventory AII, in fact, 
differs significantly from the other existing tools as AII is designed to screen for possibly atopic 
subjects, while the commonly used questionnaires only allow the quantification of the severity of 
symptoms and monitoring of therapy effects. 
Conversely, a limitation of this study is that, with atopy, it is almost impossible to select a control 
group of unquestionably non-atopic individuals [15] since it is widely accepted that the diagnosis of 
atopy is complex and it is only confirmed by the expression of atopic symptoms, which might occur 
later on at any age [23].  
The validation analysis allowed us to keep all 11 items, resulting in a questionnaire that could be 
applied rapidly enough to use for screening. In fact, the data showed that eliminating the questions 
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(r6, r7) with the lowest accuracy did not provide enough evidence of differences in the results, while 
causing a significant reduction in sensitivity. We also observed that the item s1 (“Do you think you 
suffer from an allergy or have you received medical treatments for allergies?) had 100% specificity 
but provided 28% of the false negative results when asked alone. Even combining the 2 items with 
the highest accuracy (s1, r1) resulted in the index not being accurate enough.  
Interestingly, the occlusal condition (r1) gave the highest accuracy, odds ratio and logistic 
coefficients. While not directly correlated to allergic diseases, the position of the teeth was able to 
identify the “atopic” patients in 96% of cases. The relationship between atopy and teeth position 
might be explained by the chronic oral breathing in the atopic subjects since a low position of the 
tongue and narrowing of the palate have been found to be associated with protrusion of the upper 
incisors [33-36]. 
As highlighted in the European Academy of Allergy and Clinical Immunology (EAACI) position paper 
for Rhinology in 2011 [19], “the patients' history is vital in understanding and diagnosing the problem. 
In rhinitis and rhinosinusitis an accurate history is usually more important than any other 
investigation.”  
Our data confirm that atopic patients are easily identifiable when they express the classic symptoms 
of allergic sensitization (the “decisive” questions of the AII) but they may be underdiagnosed when 
their symptoms are related to minimal persistent inflammation of the upper airways due to 
sensitization to aero-allergens, which is investigated by the “probability” items. To our knowledge, 
the AII is the first reliable and simple tool designed specifically for the initial identification of the 
condition of “atopy” also in such patients accessing the ENT clinic. 
Based on the promising results of this study it would be useful and interesting to test the AII in other 
clinical settings or in more extensive ENT fields, in order to select those who should be referred to an 
immunologist or should be provided an initial symptoms-relieving therapy. 
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FIGURE LEGENDS  
Figure 1. ROC curve 
Figure 2. Plot of the responses calculated b y  multiplying the binary responses of the 11 variables 
by their accuracies; separated histograms and fitted poisson distributions are plotted (red: “atopic” 
and green: healthy “control” group) 
